Indication
Highly Sensitized Patients on Waiting List for Kidney Transplantation
1 clinical trial
3 products
Clinical trial
A Phase 2 Open-label, Prospective, Randomized Study of Inebilizumab, VIB4920, or the Combination to Evaluate Safety and Tolerability in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased DonorStatus: Withdrawn, Estimated PCD: 2021-12-01
Product
InebilizumabProduct
VIB4920Product
Inebilzumab+VIB4920